Reuters logo
4 months ago
BRIEF-Agios Pharmaceuticals announces MTAP pathway research program and collaboration agreement with Celgene
March 13, 2017 / 1:54 PM / 4 months ago

BRIEF-Agios Pharmaceuticals announces MTAP pathway research program and collaboration agreement with Celgene

1 Min Read

March 13 (Reuters) - Agios Pharmaceuticals Inc

* Agios announces MTAP pathway research program as development program and development candidate under master research and collaboration agreement with Celgene

* Says Celgene will pay Agios an $8 million designation fee for MTAP pathway program

* Agios Pharmaceuticals Inc - Celgene will have an opt-in right on program up through Phase 1 dose escalation for at least a $30 million fee

* Agios Pharmaceuticals Inc - Agios will be eligible for up to $169 million in clinical and regulatory milestone payments

* Agios Pharmaceuticals - co, Celgene to have global co-development and co-commercialization rights with worldwide 50/50 cost and profit share on MTAP pathway program Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below